Ardsley Advisory Partners’s Actinium Pharmaceuticals ATNM Stock Holding History

Ardsley Advisory Partners’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-4,333	Closed	-$46K	–	148
2020 Q2	$46K	Buy	4,333 +1,833	+73%	+$13.9K	0.01%	127
2020 Q1	$15K	Hold	2,500	–	–	0.01%	100
2019 Q4	$16K	Hold	2,500	–	–	﹤0.01%	150
2019 Q3	$17K	Hold	2,500	–	–	﹤0.01%	132
2019 Q2	$19K	Hold	2,500	–	–	﹤0.01%	148
2019 Q1	$36K	Sell	2,500 -167	-6%	-$2.67K	0.01%	128
2018 Q4	$31K	Hold	2,667	–	–	0.01%	101
2018 Q3	$59K	Buy	+2,667	New	+$54.3K	0.01%	148

Other funds holding ATNM

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Ardsley Advisory Partners's ATNM Position: Q3 2020 in Review

Ardsley Advisory Partners sold out of Actinium Pharmaceuticals (ATNM) in Q3 2020, closing a stake of 4,333 shares — an estimated $46K sold.

Ardsley Advisory Partners first reported a position in ATNM in Q3 2018 and held it in 8 quarters. The position peaked at $59K in Q3 2018. 41 funds tracked by Wall St. Rank hold ATNM as of Q3 2020.

Ardsley Advisory Partners reported no remaining Actinium Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Ardsley Advisory Partners sold 4,333 Actinium Pharmaceuticals shares in Q3 2020, an estimated $46K.
Ardsley Advisory Partners first reported a position in Actinium Pharmaceuticals in Q3 2018 and held it in 8 quarters.
Ardsley Advisory Partners's Actinium Pharmaceuticals position peaked at $59K in Q3 2018.
41 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q3 2020.

Based on Ardsley Advisory Partners's 13F filing for Q3 2020, filed 13 Nov 2020.